12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zadaxin thymalfasin regulatory update

SciClone said a reduction in the Chinese retail list price for Zadaxin thymalfasin will have less of an effect on revenues for the cancer and infectious disease drug than previously expected. China's National...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >